2,543.00
-26(-1.01%)
Currency In JPY
Address
Otemachi Financial City Grand Cube
Tokyo, 100-0004
Japan
Phone
81 3 5205 7200
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
5669
First IPO Date
January 04, 2000
| Name | Title | Pay | Year Born |
| Mr. Masashi Miyamoto Ph.D. | Chairman & Chief Executive Officer | 157M | 1959 |
| Hiroki Nakamura | Global Corporate Communications Head | 0 | N/A |
| Mr. Takeyoshi Yamashita Ph.D. | Director, Executive Vice President & Chief Medical Officer | 0 | 1961 |
| Kazuki Nemoto | Head of Global Legal | 0 | N/A |
| Ms. Shoko Itagaki | Managing Executive Officer, Chief People Officer & Global Human Resources Head | 0 | N/A |
| Dr. Abdul Hafeez Mullick Ph.D. | Representative Director, President & Chief Operating Officer | 0 | 1967 |
| Mr. Motohiko Kawaguchi | Chief Financial Officer & Managing Executive Officer | 0 | N/A |
| Naohiko Kubo | Global Finance Head & Accounting Manager | 0 | N/A |
| Hiroshi Sonekawa | Managing Executive Officer, Vice President and Head of Sales & Marketing Division | 0 | N/A |
| Yasuo Fujii M.B.A. | Chief Strategy Officer, Vice President, Managing Executive Officer & Global BD Head | 0 | 1964 |
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.